Richard A. Young Ph.D.
Net Worth
Last updated:
What is Richard A. Young Ph.D. net worth?
The estimated net worth of Dr. Richard A. Young Ph.D. is at least $1,603,526 as of 16 Sep 2024. He owns shares worth $44 as insider, has earned $283,482 from insider trading and has received compensation worth at least $1,320,000 in Syros Pharmaceuticals, Inc..
What is the salary of Richard A. Young Ph.D.?
Dr. Richard A. Young Ph.D. salary is $165,000 per year as Scientific Founder, Member of Scientific Advisory Board & Director in Syros Pharmaceuticals, Inc..
How old is Richard A. Young Ph.D.?
Dr. Richard A. Young Ph.D. is 71 years old, born in 1954.
What stocks does Richard A. Young Ph.D. currently own?
As insider, Dr. Richard A. Young Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. (SYRS) | Scientific Founder, Member of Scientific Advisory Board & Director | 8,000 | $0.01 | $44 |
What does Syros Pharmaceuticals, Inc. do?
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Richard A. Young Ph.D. insider trading
Syros Pharmaceuticals, Inc.
Dr. Richard A. Young Ph.D. has made 19 insider trades between 2017-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 34,837 units of SYRS stock on 28 Jun 2024. As of 16 Sep 2024 he still owns at least 8,000 units of SYRS stock.
Syros Pharmaceuticals key executives
Syros Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. David A. Roth (62) Chief Medical Officer
- Dr. Eric R. Olson (67) Chief Scientific Officer
- Dr. Nancy A. Simonian M.D. (64) Pres, Chief Executive Officer & Director
- Dr. Richard A. Young Ph.D. (71) Scientific Founder, Member of Scientific Advisory Board & Director